

# *PNSG Meeting Minutes*

## *1.1. Purpose*

The purpose of this document is to capture details of the Project Nexus Steering Group meeting in order for wider sharing and confirmation and follow up of actions.

## *1.2. Meeting Details*

<b>Meeting Name:</b>	<b>Project Nexus Steering Group</b>
<b>Meeting Date:</b>	21/11/16
<b>Meeting Time:</b>	10:00 – 12:00pm
<b>Meeting Format/Location:</b>	Ofgem with WebEx facility
<b>Chaired by:</b>	Rob Salter-Church
<b>Minutes recorded by:</b>	PwC

## *1.3. Meeting Attendees*

<b>Group</b>	<b>Company</b>	<b>Representatives</b>	<b>Company</b>	<b>Representatives</b>
6 Largest Suppliers	NPower	Chris Harden	Ofgem	Rob Salter-Church
	E.ON	Alex Travell	Ofgem	Jon Dixon
Challenger	Flow Energy	Robert Cameron-Higgs	Ofgem	Nicola Garland
	Utilita	Ali Russell	Ofgem	Tricia Quinn
GT	SGN	Steve Simmons	PwC	Steve Mullins
	National Grid Distribution	Chris Warner	PwC	Gill Williams
I&C	DONG Energy	Lorna Lewin	PwC	Richard Shilton
	ICoSS Group	Gareth Evans	PwC	Melisa Findlay
iGT	ES Pipelines	Vicki Spiers	Xoserve	Ellen Hughes
			Xoserve	Sandra Simpson
			Xoserve	Paul Toolin
			Baringa	James Beverley

## *1.4. Meeting Agenda*

1. Agenda and approval of minutes
2. PNSG programme summary
3. Market Trials Exit
4. Workstream Summary
5. PNSG Decisions
6. AOB

## 1.5. Decision Log

Decision #	Pillar/ Milestone	Decision	Decision Owner	Status	Target Date
D008	Data: D1.4 Pre IDR2 Delta Load Testing complete	Based upon PNDG recommendation from the 16 Nov 16, the PNSG were requested to ratify the move of milestone D1.4 [Pre IDR2 Delta Load Testing Complete] from 23 Dec 16 to 23 Jan 16.	PNSG	<b>Closed</b>	21/11/2016
Status:	Endorsed at PNSG held 21 Nov 16.				
D009	Data: D1.1 Pre IDR2 US Data Load Testing Complete and D1.2 Pre IDR2 iGT Data Load Testing Complete	PNSG were requested to endorse the change in date of milestones D1.1 [Pre IDR2 US Data Load Testing Complete] and D1.2 [Pre IDR2 iGT Data Load Testing Complete] from 20 Oct 16 to the 27 Feb 17.	PNSG	<b>Closed</b>	21/11/2016
Status:	Endorsed at PNSG held 21 Nov 16.				
D010	Contingency Checkpoint #1	The first of three contingency checkpoints scheduled within the Project Nexus programme has been reached. Based upon the successful completion of Delta TC3 and the completion of MT exit, it is assessed that there is no requirement to invoke the use of the planned contingency period and delivery will continue against a 01 Jun 17 go-live date. The PNSG were requested to endorse the decision not to invoke the planned contingency at this checkpoint.	PNSG	<b>Closed</b>	21/11/2016
Status:	Endorsed at PNSG held 21 Nov 16.				
D011	Market Trials: MT 1.5 Market Trials Complete	The PNSG were requested to ratify that MT 1.5 [Market Trials Complete] has been realised and that this phase of the programme is now complete.	PNSG	<b>Closed</b>	21/11/2016
Status:	Endorsed at PNSG held 21 Nov 16. The PNSG have ratified that milestone MT1.5 (Market Trials complete) has been realised with conditions and that this phase of the programme is now complete subject to the agreed outstanding items being completed between now and the end of the industry regression testing period.				
D012	Contingency Checkpoint #2	PNSG were requested to endorse a change in scope to the industry checkpoint scheduled for 23 Dec 16 to include iGT and US loads within the criteria to be assessed. Specifically: <ul style="list-style-type: none"> <li>●IGT loads is progressing against scheduled delivery timeline</li> <li>●US loads is progressing against scheduled delivery timeline</li> </ul>	PNSG	<b>Closed</b>	21/11/2016

Status:	Endorsed at PNSG held 21 Nov 16.
---------	----------------------------------

### 1.6. Actions arising from the meeting on 21 November 2016

Action #	Pillar/ Milestone	Action	Action Owner	Status	Date Raised	Due Date
A177	Solution Delivery	Baringa to provide a view on the attainment of Xoserve code stability at MT2.4.	Baringa	New	21 Nov 16	6th Jan (at MT2.4)
A178	Market Trials	For outstanding test lines from Managed Market Trials, provide detail of the residual test activity on an anonymised basis to PNDG.	PwC	New	21 Nov 16	01 Dec 16

### 1.7. Actions arising from previous meetings

Action #	Pillar/ Milestone	Action	Progress	Action Owner	Status	Date Raised	Due Date
Action 123	Market Trials	Undertake a review of P3 defects to identify any that do not need to be fixed for go-live. Agree these with the market participants.	In progress. This action has to be done in conjunction with the industry and this will be agreed through the defect management process. As part of this process, the workaround process has been defined and agreed at MTWG. The due date has been moved to reflect the end of the managed Market Trials phase.	Xoserve, PwC and Market Participants	Overdue	26 Jul 16	31 Aug 16 → 23 Sep 16 → 14 Oct 16 → 11 Nov 16 → 30 Nov 16
Action 138	Market Trials	Xoserve to i) confirm the final list of files and reports unchanged by Nexus. In addition indicate which are platform independent (CMS) and which are unchanged but now part of the SAP ISU solution.	This work is ongoing and will be shared with the industry by 30 Nov 16. The due date has been updated to reflect this.	Xoserve	Open	22 Aug 16	26 Sep 16 → 28 Sep 16 → 05 Oct 16 → 14 Oct 16 → 26 Oct 16 → 30 Nov 16

Action #	Pillar/ Milestone	Action	Progress	Action Owner	Status	Date Raised	Due Date
		<p>ii) Xoserve to demonstrate the level of internal testing carried out, or planned to be carried out on these files and reports.</p> <p>iii) Share the above analysis with all participants to review and determine if they need to include in their MT Regression plans. Where participants do want to include files/reports in MT regression plans they need to provide a rationale as part of their entry submission.</p>					
A171	N/A	<p>Seek input from Market Participants on their ability to shift with a change of programme go live date (only if needed) on 19 Nov 16, 23 Dec 16, 27 Jan 16 in line with the enactment of contingency checkpoints. Request also rationale for above and also 'latest shift date'.</p>	<p>17 responses received to the email request. PNSG requested PwC to issue the email again for further input.</p> <p>PwC will present a refresh to this at the next PNSG with an overlay of the contingency checkpoints.</p>	PwC	Open	24 Oct 16	31 Oct 16 → 19 Dec 16
A172	Market Trials	<p>Take account of agreed post 11 Nov 16 items when determining participant RAG statuses in managed MT</p>		PwC	Closed	24 Oct 16	31 Oct 16

---

## 1.8. Meeting Minutes

---

### Item 1: Agenda and approval of minutes

---

#### Introduction

1. Rob Salter-Church (Ofgem) opened the meeting. The board approved the minutes from the previous PNSG.

---

### Item 2: PNSG Programme Summary

---

1. The overall programme status is reporting Amber-Green against the proposed 1 June 2017 implementation date, due to Market Trials Exit and Data improvements. Steve Mullins (PwC) provided commentary around the programme pillars.
2. Market Trials has a dedicated agenda item to follow. It should be noted that the Amber rating is forward looking based on what needs to happen to ensure readiness for MT regression.
3. In the GONG workstream, participants were asked to review the GONG evidence requirements. Two Webex calls took place last week to walk through the process. A question arose regarding if the GONG criteria had been socialised before they were baselined. It was confirmed that the criteria for both Market Participants and Xoserve were issued on 2 June 2016, with a request for feedback. The GONG questionnaire was issued 3 weeks ago to participants, which also allowed for feedback and discussion.

---

### Item 3: Market Trials Exit

---

#### Market Trials Exit

4. Richard Shilton (PwC) provided an overview of the MT Exit decision, with supporting evidence. Ofgem had made the indicative decision to exit L3/4 Market Trials on 11 November 2016, following the 4 November 2016 portal submission and review of the Managed Market Trials test plans, which gave evidence of good coverage across mandatory scenarios and identification of mitigating actions needed.
5. It was confirmed that there are only a limited number defect workarounds with a larger focus on fixes.
  - Note: The process to agree workarounds takes place at the Market Trials Working Group.
6. Sandra Simpson (Xoserve) clarified that any further defects found ahead of the start of regression testing can be logged through the service desk in order for Xoserve to obtain visibility, and a light level triage is occurring to assess the impact of these defects.
  - Currently, only approximately 5 such defects have been logged.
  - The focus for defect fixes is on those defects raised through managed Market Trials, but fixes for further defects raised will take place if there is the opportunity to do so and if the initial triage identifies a significant issue
7. A suggestion was made to include an MT Regression entry measure of defects. Richard Shilton (PwC) explained that this was already in place and the Market Trials PNDG report would be repositioned to include activities in the entry to the MT regression phase for greater visibility.
8. The final Market Trials Portal Submission on 4 November represented 94% coverage of AQ. Another participant has now engaged, bringing this to 97%. 9 participants have had limited or no engagement in Market Trials (approximately 2% of AQ), and further letters will be issued to them to remind them of obligations.
  - With regards to mandatory scenarios, those marked blocked or failed link back to what is known from Market Trials test plans, which have resolution plans in place already.
  - It's important to note that blocked or failed does not mean a complete block or failure and often refers to very specific conditions.

- 
- For market critical processes, an amber rating represents that the criteria for green has not been met (100% complete of C1 & 2 scenarios) but mitigation plans are in place.
  - The defect RAG rating moved from red to amber, following credible mitigation plans being put in place by Xoserve and having a known defect position.
  - The Market Trials team are following up on those participants with outstanding tests to ensure completion.
  - Clarification made after the meeting: 'Test exceptions' as noted on slide 7 and 10 of the PNSG pack are defined as residual activity required from L3/4 Market Trials.
9. It was confirmed that by the end of regression testing, the majority of those mandatory scenarios marked 'in progress' should be complete, other than those where testing can be deferred until after go-live. Often these relate to specific elements, not the whole scenario.
  10. Regarding the production environment and facilities for testing post go-live, this will initially fall in the remit of Post Implementation Support (PIS), followed by an enduring environment that is currently in discussion via Xoserve's consultation on their business plan.
  11. Sandra Simpson (Xoserve) outlined the Market Trials Xoserve defect position.
    - The figures presented for external defects do not include any P1 or P2.
    - It was confirmed that when defects are fixed, the impacted participants will be contacted and given the opportunity to retest.
    - Workarounds have visibility in MTWG, unless this is a purely Xoserve workaround. These would also be captured in Xoserve's GONG criteria.
    - An update was provided on the participant raised defect summary, that following a further deployment the number of outstanding defects remaining under investigation has fallen from 21 to 15.
  12. There was a request for more information about UAT and Xoserve internal MT defects.
    - Xoserve indicated that UAT and internal MT defect numbers are reported through the PNDG pack.
    - Sandra Simpson (Xoserve) to distribute a full list of defects for visibility. (A174 noted in PNDG on 15 Nov 16)
  13. Richard Shilton (PwC) explained the next steps following Market Trials Exit. This includes an MT Lessons Learnt session, discussing what needs to be done for MT Regression in order to start promptly and to ensure the same issues are not encountered. This session will include MTWG and RIAG members.
  14. It was confirmed that Baringa are assessing code stability, and that they will provide a view on its attainment at the code stability milestone (MT2.4).
  15. **Decision D011: This decision to exit Level 3/4 Market Trials was passed with an agreement that the wording would be amended to acknowledge that the exit is realised with caveats and that there are points to be addressed before or during regression.**
    - Rob Salter-Church highlighted his thanks to all those involved in the completion of Market Trials, which has led to very positive progress.
  16. Questions were raised around gas settlement testing in relation to the CMA's recent proposals, and whether Nexus has been built to cope with a large increase in data volumes from smart metering. This is currently based upon information Xoserve have, therefore Sandra Simpson (Xoserve) requested that participants ensure their rollout plans are as accurate as possible. It was noted that CMA has Nexus as a priority, and any decisions will be based on current circumstances.

---

#### Item 4: Workstream Summary

---

17. Melisa Findlay (PwC) presented a summary of each workstream.
  - It was agreed that this structure will be used going forward in PNSG, to give visibility on late or changing milestones.
  - For the data workstream, it was agreed that D1.3 should be marked as complete.
18. Participants were asked by email to submit the last date they would be able to move to a contingency date of 1 July 2017. The 17 responses received were compiled and indicate a spread from December 2016 to June 2017.

- 
- Two participants identified dates either prior to or at the final contingency checkpoint in January, and discussions are needed to identify the rationale behind this.
19. A question arose around the timings of the AQ review if contingency was invoked. Rob Salter-Church (Ofgem) said he would take this away to discuss.
  20. A reminder that the distribution working group is taking place on Thursday (24 November).

---

#### **Item 5: PNSG Decisions**

---

21. **Decisions 8, 9, 10, 11 and 12 were all agreed.** See the chart on previous page for the details on this.
22. Rob Salter-Church (Ofgem) stated that there is a positive outlook, having passed the first check-point, exited Market Trials (with caveats), as well as Xoserve making better than expected progress in the data workstream. It is important to continue this momentum and ensure a prompt start to MT regression. Ofgem and PwC are working on managed regression plan this week.

---

#### **Item 6: AOB**

---

23. A concern exists around the iGT data load not completing in time frame it needs to, and when participants will know if this is a problem.
  - This was tested in IDR1 and migrated as bulk in the NED window, taking longer than time allocated. Xoserve are looking at how to speed up the process. There are iGT test cycles between now and IDR2, however this will not be completed on the production environment as the bulk load is taking place. This will be captured as a risk and as lessons learnt on IDR1.
24. The National grid split and impact on invoicing was also raised as an area of concern. There is a solution but it is a manual workaround. This will be presented on Thursday (24 November) at the Distribution work group.

---

*This document has been prepared by PwC only for Ofgem and solely for the purpose and on the terms agreed with Ofgem in PwC's statement of work (of 1 August 2016, Spec 7) as part of PwC's call-offs under the framework agreement dated 11 April 2016. PwC accept no liability (including for negligence) to anyone else in connection with our work or this document.*